Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2019 Expert Video Report on Prostate Cancer

Reporting from ESMO 2019 Congress, Johann de Bono comments on practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).

He features the results from the CARD study on best sequence treatment and from the PROfound trial with olaparib in patients whose tumours have homologous recombination repair gene alterations. He explains the need for molecular profiling of advanced prostate cancer which may have a major impact on prostate cancer management in the future.

Abstracts:

  • LBA13_PR: CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration- resistant prostate cancer
  • LBA12_PR: PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

This video was supported with an educational grant from Janssen. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings